In this work, we characterized the special immune microenvironment of high risk t(8;21) AML patients (CD34+CD117dim%-High subgroup) and evaluated longitudinal dynamic changes in the expression profiles of immune cells. This evidence concerns the gene CD34 and acute myeloid leukemia.